Market research future published a cooked research report on Global Lung Cancer Market that contains the information from 2017 to 2023. The Global Lung Cancer Market is expected to grow with a CAGR of 13.5% from 2017 to 2023.
Test the market data and market information presented through more than 88 market data tables and 35 figures spread over more than 102 numbers of pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Global Lung Cancer Market from 2017 to 2023".
The Hottest Trend in the Market
Lung cancer is a harmful tumor that originates in the cells of the lung. Harmful implies that it can spread, or metastasize, to different parts of the body. At the point when malignancy begins in lung cells, the circumstance is known as primary lung cancer. Cells in the lung sometimes change and no longer grow or behave normally. These progressions may prompt favorable tumors, for example, hamartoma and papilloma. Favorable tumors are not dangerous. But in some cases, changes to lung cells can cause cancer. Lung cancers are categorized into non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) based on the type of cell in which the cancer started. Among the types, Non–Small Cell Lung Cancer (NSCLC) and small cell lung cancer (SCLC) are compositing the growth of the market. It is projected to grow at a steady rate from the period of 2017 to 2023.
The treatments for lung cancer include surgery, chemotherapy, and radiotherapy with NSCLC responding better to surgery and SCLC usually responding better to chemotherapy and radiotherapy. The main drivers of lung cancer market are the growing environmental pollution and smoking. The rise in the cases of lung cancers in females due to rising number of female smokers will drive the market up. Another driver is the greater screening rates with a sizable portion of lung cancer are detected during screening for other diseases.
Browse report : https://www.marketresearchfuture.com/reports/lung-cancer-market-1185
Regional Analysis:
On the basis of region the global lung cancer market is segmented into North America, Europe, Asia Pacific and Middle East & Africa. The North American market is expected to be leading market globally and has captured a market share of 36.0% in 2016. In the North American market countries like US and Canada are majorly analyzed, where in the U.S., market is expected to be one of the leading markets, which is expected to reach high growth figures in 2023 from 2017, this market is expected to grow at a CAGR of 14.4% during the forecast period of 2017-2023. The factors influencing the growth of North America lung cancer market are growing healthcare expenditure, presence of major companies in the region, growing research & development funding.
Furthermore Europe is expected to be one of the second largest markets globally, which has captured around 23% of the market share of the global lung cancer market. This market is expected to grow at a CAGR of 13.8% during the forecast period 2017-2023. Countries like Germany, France and UK dominating the European market. In Asia Pacific region, China and India are expected to show a fastest growth during 2016-2023.